Sridhar Natesan

List of Publications by Year
in descending order

48 papers	2,711 citations	257450 24 h-index	302126 39 g-index
56 all docs	56 docs citations	56 times ranked	3605 citing authors

#	Article	IF	Citations
1	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	3.1	8
2	Time to re-evaluate the risks and benefits of valproate and a call for action. British Journal of Psychiatry, 2022, 221, 711-713.	2.8	1
3	Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Molecular Psychiatry, 2021, 26, 2562-2576.	7.9	60
4	A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin, 2021, 47, 1116-1129.	4.3	69
5	Synaptic Dysfunction in Schizophrenia and the Effects of Treatment: Complementary in Vivo Clinical and Preclinical Studies. Biological Psychiatry, 2021, 89, S34-S35.	1.3	0
6	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behavioural Brain Research, 2021, 405, 113203.	2.2	10
7	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
8	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology, 2020, 172, 107704.	4.1	180
9	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 64-77.	7.4	506
10	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. Schizophrenia Bulletin, 2020, 46, S28-S28.	4.3	0
11	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. Journal of Affective Disorders, 2020, 276, 991-1000.	4.1	11
12	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	12.8	148
13	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	1.3	54
14	179. Effects of Chronic Haloperidol Treatment on Brain Volume in a Rat Model in of Infection-Mediated Neurodevelopmental Disorders. Biological Psychiatry, 2019, 85, S74.	1.3	0
15	Region-specific increases in the expression of translocator protein 18kDa (TSPO) after chronic exposure to haloperidol in naÃ¯ve adult rats. European Neuropsychopharmacology, 2019, 29, S252.	0.7	0
16	T193. CHRONIC HALOPERIDOL TREATMENT INDUCES SIGNIFICANT CHANGES IN MICROGLIA AND IN THE EXPRESSION OF THE 18 KDA TRANSLOCATOR PROTEIN TSPO IN NAIVE ADULT RAT BRAINS. Schizophrenia Bulletin, 2018, 44, S191-S191.	4.3	0
17	40.3 MATERNAL IMMUNE ACTIVATION AND CHRONIC HALOPERIDOL INTERACT TO INCREASE MICROGLIAL ACTIVATION IN VIVO: DO ANTIPSYCHOTICS INFLAME THE BRAIN?. Schizophrenia Bulletin, 2018, 44, S65-S65.	4.3	0
18	Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology, 2018, 95, 28-33.	2.7	12

#	Article	IF	Citations
19	Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.. Translational Psychiatry, 2017, 7, e1027-e1027.	4.8	53
20	Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss. Psychological Medicine, 2016, 46, 3081-3093.	4.5	14
21	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
22	Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. British Journal of Psychiatry, 2016, 209, 361-365.	2.8	193
23	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
24	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 2015, 25, 2098-2107.	0.7	77
25	Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. Brain, 2015, 138, 3016-3029.	7.6	90
26	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
27	Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [11C]MP-10 PET rodent imaging study with ex vivo confirmation. Translational Psychiatry, 2014, 4, e376-e376.	4.8	16
28	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.	5.0	50
29	Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugsâ€"Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.	1.3	85
30	Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Translational Psychiatry, 2013, 3, e208-e208.	4.8	24
31	Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. Biological Psychiatry, 2012, 71, 855-863.	1.3	113
32	Reply to: Lithium and the Expanding Brain. Biological Psychiatry, 2012, 72, e19.	1.3	0
33	Antipsychotic therapy over half a century: a tale of discovery from chlorpromazine to aripiprazole. The National Medical Journal of India, 2012, 25, 193-5.	0.3	1
34	Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. Biological Psychiatry, 2011, 69, 936-944.	1.3	166
35	Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. Behavioural Brain Research, 2011, 221, 311-313.	2.2	11
36	Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. International Journal of Neuropsychopharmacology, 2011, 14, 1327-1339.	2.1	46

#	Article	IF	Citations
37	Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. Pharmacology Biochemistry and Behavior, 2011, 100, 86-89.	2.9	11
38	Partial agonists in schizophrenia â€“ why some work and others do not: insights from preclinical animal models. International Journal of Neuropsychopharmacology, 2011, 14, 1165-1178.	2.1	24
39	PARTIAL AGONISTS IN SCHIZOPHRENIA â€“ WHY SOME SUCCEED AND OTHERS DON'T. INSIGHTS FROM PRECLINICAL COMPARISONS. Schizophrenia Research, 2010, 117, 383-384.	2.0	0
40	Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. European Neuropsychopharmacology, 2009, 19, 416-430.	0.7	21
41	The antipsychotic potential of l-stepholidineâ€"a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology, 2008, 199, 275-289.	3.1	53
42	Amisulpride the â€˜atypicalâ€™ atypical antipsychotic â€" Comparison to haloperidol, risperidone and clozapine. Schizophrenia Research, 2008, 105, 224-235.	2.0	64
43	Evaluation of N-Desmethylclozapine as a Potential Antipsychoticâ€"Preclinical Studies. Neuropsychopharmacology, 2007, 32, 1540-1549.	5.4	47
44	Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 544-547.	2.3	3
45	Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. Synapse, 2006, 60, 314-318.	1.2	11
46	Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models. Neuropsychopharmacology, 2006, 31, 1854-1863.	5.4	194
47	The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 810-818.	2.5	75
48	Contrasting loxapine to its isomer isoloxapineâ€"the critical role of in vivo D2 blockade in determining atypicality. Schizophrenia Research, 2005, 77, 189-199.	2.0	12